MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East.
Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م103.58|
|52 Week High||ج.م72.50|
|52 Week Low||ج.م132.07|
|1 Month Change||-1.87%|
|3 Month Change||4.17%|
|1 Year Change||38.11%|
|3 Year Change||21.86%|
|5 Year Change||81.72%|
|Change since IPO||1,039.38%|
Recent News & Updates
|MIPH||EG Pharmaceuticals||EG Market|
Return vs Industry: MIPH exceeded the EG Pharmaceuticals industry which returned -0.2% over the past year.
Return vs Market: MIPH exceeded the EG Market which returned 12.2% over the past year.
Stable Share Price: MIPH is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: MIPH's weekly volatility (5%) has been stable over the past year.
About the Company
|1958||n/a||Wafik El Bardissi||https://www.minapharm.com|
MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East. The company’s products include Angiofox capsules, Artelac and Berberil eye drops; Bon-one, Ciprodiazole, Dumozol, Hydroquine, and Burinex tablets; Chlorhexidine; DICYNONE; Cornerege fluid and ophthalmic gel; Betolvex and Fleboton ampoules; Deponit patches; Dexagel viscous eye drops; Doxiproct plus and Doxiproct ointment; Doxium capules; Broncho-Vaxom capsules for adults and infants; Broncho-Vaxom infant sachets; Effox tablets and capsules; and Extrauma cream, haemorrhoids, and forte gel. It also provides Ferro sanol duodenal, Lipanthyl, Parafon, Ribavirin, Uro-Vaxom, Ursofalk, Ursoplus, Ursotwin, and Ferro Sanol Gyn capsules; Gyno-Pevaryl, Pevisone, Srilane, and Pevaryl cream; Gonapure; Hair Plus Back 2% and 5%; Hair Plus Back Topical FOAM; Lucidril 500; Lucidril, Salofalk, Trimed flu, XerovirinC, and Ossopan tablets; Thrombexx ampoules, cream, and gel; Vidisept N drops; and Luciforte, Oxytocin, Reiferon Retard, and Nausilex ampoules.
MINAPHARM Pharmaceuticals Fundamentals Summary
|MIPH fundamental statistics|
Is MIPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MIPH income statement (TTM)|
|Cost of Revenue||ج.م1.64b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||34.79|
|Net Profit Margin||15.53%|
How did MIPH perform over the long term?See historical performance and comparison
2.6%Current Dividend Yield
Is MINAPHARM Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MIPH (EGP103.58) is trading above our estimate of fair value (EGP81.44)
Significantly Below Fair Value: MIPH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MIPH is good value based on its PE Ratio (3x) compared to the African Pharmaceuticals industry average (15.7x).
PE vs Market: MIPH is good value based on its PE Ratio (3x) compared to the EG market (8.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MIPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MIPH is good value based on its PB Ratio (0.7x) compared to the XF Pharmaceuticals industry average (2x).
How is MINAPHARM Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MINAPHARM Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has MINAPHARM Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MIPH has high quality earnings.
Growing Profit Margin: MIPH's current net profit margins (15.5%) are higher than last year (10.2%).
Past Earnings Growth Analysis
Earnings Trend: MIPH's earnings have grown significantly by 33.5% per year over the past 5 years.
Accelerating Growth: MIPH's earnings growth over the past year (98%) exceeds its 5-year average (33.5% per year).
Earnings vs Industry: MIPH earnings growth over the past year (98%) exceeded the Pharmaceuticals industry 10%.
Return on Equity
High ROE: MIPH's Return on Equity (24.8%) is considered high.
How is MINAPHARM Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: MIPH's short term assets (EGP2.5B) exceed its short term liabilities (EGP1.7B).
Long Term Liabilities: MIPH's short term assets (EGP2.5B) exceed its long term liabilities (EGP388.9M).
Debt to Equity History and Analysis
Debt Level: MIPH's debt to equity ratio (62.5%) is considered high.
Reducing Debt: MIPH's debt to equity ratio has increased from 39.4% to 62.5% over the past 5 years.
Debt Coverage: MIPH's debt is well covered by operating cash flow (40.3%).
Interest Coverage: MIPH's interest payments on its debt are well covered by EBIT (13.2x coverage).
What is MINAPHARM Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MIPH's dividend (2.61%) isn’t notable compared to the bottom 25% of dividend payers in the EG market (2.61%).
High Dividend: MIPH's dividend (2.61%) is low compared to the top 25% of dividend payers in the EG market (7.87%).
Stability and Growth of Payments
Stable Dividend: MIPH has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: MIPH has only been paying a dividend for 4 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (7.8%), MIPH's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Wafik El Bardissi
Dr. Wafik Saad El Bardissi serves as the Executive Chairman and Chief Executive Officer at Minapharm Pharmaceuticals SAE.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
MINAPHARM Pharmaceuticals's employee growth, exchange listings and data sources
- Name: MINAPHARM Pharmaceuticals
- Ticker: MIPH
- Exchange: CASE
- Founded: 1958
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ج.م1.273b
- Shares outstanding: 12.29m
- Website: https://www.minapharm.com
- MINAPHARM Pharmaceuticals
- El-Bardissi Street
- 2T Takseem Asmaa Fahmy Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 16:48|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.